🚀 VC round data is live in beta, check it out!
Neuren Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Neuren Pharma and similar public comparables like Alvotech, Guilin Sanjin, Septerna, GNI Group and more.
Neuren Pharma Overview
About Neuren Pharma
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Founded
2004
HQ
Employees
19
Website
Sectors
Financials (LTM)
EV
$1B
Neuren Pharma Financials
Neuren Pharma reported last 12-month revenue of $48M and EBITDA of $17M.
In the same LTM period, Neuren Pharma generated $17M in EBITDA and $19M in net income.
Revenue (LTM)
Neuren Pharma P&L
In the most recent fiscal year, Neuren Pharma reported revenue of $152M and EBITDA of $125M.
Neuren Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $48M | XXX | $152M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $152M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | $17M | XXX | $125M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 82% | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 82% | XXX | XXX | XXX |
| Net Profit | $19M | XXX | $101M | XXX | XXX | XXX |
| Net Margin | 40% | XXX | 67% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Neuren Pharma Stock Performance
Neuren Pharma has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Neuren Pharma's stock price is $9.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.6% | XXX | XXX | XXX | $0.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeuren Pharma Valuation Multiples
Neuren Pharma trades at 21.6x EV/Revenue multiple, and 62.3x EV/EBITDA.
EV / Revenue (LTM)
Neuren Pharma Financial Valuation Multiples
As of March 19, 2026, Neuren Pharma has market cap of $1B and EV of $1B.
Equity research analysts estimate Neuren Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neuren Pharma has a P/E ratio of 64.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 21.6x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 62.3x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBIT | 60.0x | XXX | 8.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 6.8x | XXX | XXX | XXX |
| P/E | 64.7x | XXX | 12.3x | XXX | XXX | XXX |
| EV/FCF | 14.3x | XXX | (128.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neuren Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Neuren Pharma Margins & Growth Rates
Neuren Pharma's revenue in the last 12 month grew by 42%.
Neuren Pharma's revenue per employee in the last FY averaged $2.5M.
Neuren Pharma's rule of 40 is 77% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neuren Pharma's rule of X is 139% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Neuren Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | (70%) | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 82% | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | (86%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 77% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 139% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 66% | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Neuren Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alvotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Guilin Sanjin | XXX | XXX | XXX | XXX | XXX | XXX |
| Septerna | XXX | XXX | XXX | XXX | XXX | XXX |
| GNI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| HBM Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neuren Pharma M&A Activity
Neuren Pharma acquired XXX companies to date.
Last acquisition by Neuren Pharma was on XXXXXXXX, XXXXX. Neuren Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Neuren Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeuren Pharma Investment Activity
Neuren Pharma invested in XXX companies to date.
Neuren Pharma made its latest investment on XXXXXXXX, XXXXX. Neuren Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Neuren Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neuren Pharma
| When was Neuren Pharma founded? | Neuren Pharma was founded in 2004. |
| Where is Neuren Pharma headquartered? | Neuren Pharma is headquartered in United States. |
| How many employees does Neuren Pharma have? | As of today, Neuren Pharma has over 19 employees. |
| Who is the CEO of Neuren Pharma? | Neuren Pharma's CEO is Jonathan Pilcher. |
| Is Neuren Pharma publicly listed? | Yes, Neuren Pharma is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Neuren Pharma? | Neuren Pharma trades under NEU ticker. |
| When did Neuren Pharma go public? | Neuren Pharma went public in 2005. |
| Who are competitors of Neuren Pharma? | Neuren Pharma main competitors are Alvotech, Guilin Sanjin, Septerna, GNI Group. |
| What is the current market cap of Neuren Pharma? | Neuren Pharma's current market cap is $1B. |
| What is the current revenue of Neuren Pharma? | Neuren Pharma's last 12 months revenue is $48M. |
| What is the current revenue growth of Neuren Pharma? | Neuren Pharma revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Neuren Pharma? | Current revenue multiple of Neuren Pharma is 21.6x. |
| Is Neuren Pharma profitable? | Yes, Neuren Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neuren Pharma? | Neuren Pharma's last 12 months EBITDA is $17M. |
| What is Neuren Pharma's EBITDA margin? | Neuren Pharma's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Neuren Pharma? | Current EBITDA multiple of Neuren Pharma is 62.3x. |
| What is the current FCF of Neuren Pharma? | Neuren Pharma's last 12 months FCF is $72M. |
| What is Neuren Pharma's FCF margin? | Neuren Pharma's last 12 months FCF margin is 151%. |
| What is the current EV/FCF multiple of Neuren Pharma? | Current FCF multiple of Neuren Pharma is 14.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.